Fundamental study for development of a peptide vaccine against hepatitis C virus

• Project/Area Number: 20590799
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Kurume University
• Principal Investigator: YAMADA Akira Kurume University, 先端癌治療研究センター, 教授 (50158177)
• Project Period (FY): 2008 – 2010
• Project Status: Completed (Fiscal Year 2010)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: ウイルス / 感染症 / 免疫学

Research Abstract

Fundamental studies for development of therapeutic and prophylactic vaccines against hepatitis C and liver cancers.
(1) New immuno-potentiator (adjuvant) was developed and its safety and immune-potentiating activity have been demonstrated in both animal and human.
(2) Hepatitis C vaccine applicable for virtually 100% of HLA types of Japanese was developed and its safety and immunological effects have been demonstrated in human clinical trials.
(3) Decrease of virus RNA and normalization of liver function (ALT) were observed in clinical trials. Prophylactic effect of vaccination against carcinogenesis and recurrence of HCV-related liver cancers was also observed.

Research Products

• [Journal Article] Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. (2011)
  • Author(s): Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K.
  • Journal Title: Cancer Biol Ther. 12;10(12) Pages: 1266-79
• [Journal Article] A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. (2011)
  • Author(s): Noguchi M, Uemura H, Naito N, Akaza H, Yamada A, Itoh K.
  • Journal Title: Prostate 71(5) Pages: 470-9
• [Journal Article] Characteristics of severe adverse events after peptide vaccination for advanced cancer patients : analysis of 500 cases. (2011)
  • Author(s): Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, Yanagimoto H, Kawano K, Itoh K, Yamada A.
  • Journal Title: Oncol Report 25(1) Pages: 57-62
• [Journal Article] Phase I trial of a personalized Peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. (2011)
  • Author(s): Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, Itoh K.
  • Journal Title: J Clin Oncol. 20;29(3) Pages: 337-44
• [Journal Article] Phase-I clinical study of a personalized peptide vaccination available for six different HLA (HLA-A2, -A3, -A11, -A24, -A31, and -A33)-positive patients with advanced cancer. (2011)
  • Author(s): Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K.
  • Journal Title: Exp Ther Med. 2 Pages: 109-117
• [Journal Article] Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. (2011)
  • Author(s): Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K.
  • Journal Title: Cancer Biol Ther. Volume: 10(12) Pages: 1266-1279
  • Peer Reviewed
• [Journal Article] A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. (2011)
  • Author(s): Noguchi M, Uemura H, Naito N, Akaza H, Yamada A, Itoh K.
  • Journal Title: Prostate. Volume: 71(5) Pages: 470-479
  • Peer Reviewed
• [Journal Article] Characteristics of severe adverse events after peptide vaccination for advanced cancer patients : analysis of 500 cases. (2011)
  • Author(s): Yoshida K, Noguchi M, Mine T, Komatsu N, Yutani S, Ueno T, Yanagimoto H, Kawano K, Itoh K, Yamada A.
  • Journal Title: Oncol Report Volume: 25(1) Pages: 57-62
  • Peer Reviewed
• [Journal Article] Phase I trial of a personalized Peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme. (2011)
  • Author(s): Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, Itoh K
  • Journal Title: J Clin Oncol. Volume: 29(3) Pages: 337-344
  • Peer Reviewed
• [Journal Article] Phase-I clinical study of a personalized peptide vaccination available for six different HLA (HLA-A2, -A3, -All, -A24, -A31, and-A33)-positive patients with advanced cancer. (2011)
  • Author(s): Yamada A, Noguchi M, Komatsu N, Suekane S, Yutani S, Moriya F, Mine T, Momozono K, Kawano K, Itoh K.
  • Journal Title: Exp Ther Med. Volume: 2 Pages: 109-117
  • Peer Reviewed
• [Journal Article] A randomized phase II trial of personalized peptide vaccine plus low dose estramustine (EMP) versus standard dose EMP in patients with hormone refractory prostate cancer. (2010)
  • Author(s): Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Moriya F, Suekane S, Komatsu N, Yamada A, Itoh K.
  • Journal Title: Cancer Immunol.Immunother. 59(7) Pages: 1001-9
• [Journal Article] Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. (2010)
  • Author(s): Iseki K, Matsunaga H, Komatsu N, Suekane S, Noguchi M, Itoh K, Yamada A.
  • Journal Title: Cancer Sci. 101(10) Pages: 2110-4
  • NAID: 10027832060
• [Journal Article] Prophylactic effect of peptide vaccination against hepatocellular carcinoma associated with hepatitis Cvirus. (2010)
  • Author(s): Komatsu N, Yutani S, Yamada A, Shichijo S, Yoshida K, Itou M, Kuromatsu R, Ide T, Tanaka M, Sata M, Itoh K.
  • Journal Title: Exp Ther Med. 1(4) Pages: 619-626
• [Journal Article] Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. (2010)
  • Author(s): Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K.
  • Journal Title: Eur J Cancer. 46(9) Pages: 1514-9
• [Journal Article] A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. (2010)
  • Author(s): Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, Tani T, Yamada A, Kwon A, Komatsu N, Itoh K, Noguchi M.
  • Journal Title: Oncol Rep. 24(3) Pages: 795-801
• [Journal Article] A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. (2010)
  • Author(s): Matsumoto K, Noguchi M, Satoh T, Tabata KI, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K.
  • Journal Title: BJU Int. 16
• [Journal Article] A randomized phase II trial of personalized peptide vaccine plus low dose estramustine (EMP) versus standard dose EMP in patients with hormone refractory prostate cancer. (2010)
  • Author(s): Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Moriya F, Suekane S, Komatsu N, Yamada A, Itoh K.
  • Journal Title: Cancer Immunol.Immunother. Volume: 59(7) Pages: 1001-1009
  • Peer Reviewed
• [Journal Article] Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. (2010)
  • Author(s): Iseki K, Matsunaga H, Komatsu N, Suekane S, Noguchi M, Itoh K, Yamada A.
  • Journal Title: Cancer Sci. Volume: 101(10) Pages: 2110-2114
  • NAID: 10027832060
  • Peer Reviewed
• [Journal Article] Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. (2010)
  • Author(s): Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K.
  • Journal Title: Eur J Cancer. Volume: 46(9) Pages: 1514-1519
  • Peer Reviewed
• [Journal Article] A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. (2010)
  • Author(s): Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, Tani T, Yamada A, Kwon A, Komatsu N, Itoh K, Noguchi M.
  • Journal Title: Oncol Rep. Volume: 24(3) Pages: 795-801
  • Peer Reviewed
• [Journal Article] A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. (2010)
  • Author(s): Matsumoto K, Noguchi M, Satoh T, Tabata KI, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K.
  • Journal Title: BJU Int.
  • Peer Reviewed
• [Journal Article] Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients (2010)
  • Author(s): Hattori T, Mine T, Komatu N, Yamada A, Itoh K, Shiozaki H, Okuno K.
  • Journal Title: Cancer Immunol.Immunother. (in press)
  • Peer Reviewed
• [Journal Article] A randomized phase II trial of personalized peptide vaccine pluslow dose estramustine(EMP)versus standard dose EMP in patients with hormone refractory prostate cancer (2010)
  • Author(s): Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Moriya F, Suekane S, Komatsu N, Yamada A, Itoh K.
  • Journal Title: Cancer Immunol.Immunother. (in press)
  • Peer Reviewed
• [Journal Article] Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. (2009)
  • Author(s): Hattori T, Mine T, Komatu N, Yamada A, Itoh K, Shiozaki H, Okuno K.
  • Journal Title: Cancer Immunol.Immunother. 58(11) Pages: 1843-52
• [Journal Article] A peptide derived from hepatitis C virus (HCV) core protein inducing cellular responses in patients infected with HCV with various HLA class IA allele. (2009)
  • Author(s): Niu Y, Komatsu N, Komohara Y, Matsueda S, Yutani S, Ishihara Y, Itou M, Yamada A, Itoh K, Shichijo S.
  • Journal Title: J.Med.Virol. 81(7) Pages: 1232-40
• [Journal Article] Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different HLA-class I-A alleles. (2009)
  • Author(s): Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, Itou M, Kuromatu R, Ide T, Tanaka M, Sata M, Yamada A, Itoh K.
  • Journal Title: Cancer Science 100(10) Pages: 1935-42
• [Journal Article] Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. (2009)
  • Author(s): Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
  • Journal Title: Lung Cancer. 64(3) Pages: 326-33
• [Journal Article] Recent advances in cancer vaccines : an overview. (2009)
  • Author(s): Itoh K, Yamada A, Mine T, Noguchi M.
  • Journal Title: Jpn J Clin Oncol. 39(2) Pages: 73-80
• [Journal Article] A peptide derived from hepatitis C virus(HCV)core protein inducing cellular responses in patients infected with HCV with various HLA class IA allele (2009)
  • Author(s): Niu Y, Komatsu N, Komohara Y, Matsueda S, Yutani S, Ishihara Y, Itou M, Yamada A, Itoh K, Shichijo S.
  • Journal Title: J.Med.Virol. 81(7) Pages: 1232-1240
  • Peer Reviewed
• [Journal Article] Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different HLA-class I-A alleles (2009)
  • Author(s): Yutani S, Komatsu N, Shichijo S, Yoshida K, Takedatsu H, Itou M, Kuromatu R, Ide T, Tanaka M, Sata M, Yamada A, Itoh K.
  • Journal Title: Cancer Science 100(10) Pages: 1935-1942
  • Peer Reviewed
• [Journal Article] Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel (2009)
  • Author(s): Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
  • Journal Title: Lung Cancer. 64(3) Pages: 326-333
  • Peer Reviewed
• [Journal Article] A peptide derived from hepatitis C virus (HCV) core protein including cellular responses in patients infected with HCV with various HLA class IA alleles. (2009)
  • Author(s): Niu Y, Komatsu N, Komohara Y, Matsueda S, Yutani S, Is hihara Y, Itou M, Yamada A, Itoh K, Shichijo S.
  • Journal Title: J. Med. Virol. (in press)
  • Peer Reviewed
• [Journal Article] Arandomized clinical trial of an ethanol extract of Ganoderma lucidum in men with lower urinary tract symptoms. (2008)
  • Author(s): Noguchi M, Kakuma T, Tomiyasu K, Yamada A, Itoh K, Konishi F, Kumamoto S, Shimizu K, Kondo R, Matsuoka K.
  • Journal Title: Asian J.Androl. 10(5) Pages: 777-85
• [Journal Article] Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24^+ malignant glioma patients. (2008)
  • Author(s): Jin M, Komohara Y, Shichijo S, Harada M, Yamanaka R, Miyamoto S, Nikawa J, Itoh K, Yamada A.
  • Journal Title: Oncol.Report 19(5) Pages: 1277-83
• [Journal Article] EphB6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in HLA-A2+ glioma patients. (2008)
  • Author(s): Jin M, Komohara Y, Shichijo S, Nikawa J, Yamanaka R, Itoh K, Yamada A.
  • Journal Title: Cancer Sci. 99(8) Pages: 1656-62
• [Journal Article] Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. (2008)
  • Author(s): Naito M, Itoh K, Komatsu N, Yamashita Y, Shirakusa T, Yamada A, Moriya F, Ayatuka H, Mohamed ER, Matsuoka K, Noguchi M.
  • Journal Title: Prostate 68 Pages: 1753-1762
• [Journal Article] Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24^+ malignant glioma patients. (2008)
  • Author(s): Jin M, Komohara Y, Shichijo S, Harada M, Yamanaka R, Miyamoto S, Nikawa J, Itoh K, Yamada A.
  • Journal Title: Oncol. Report 19(5) Pages: 1277-1283
  • Peer Reviewed
• [Journal Article] EphB6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in HLA-A2+ glioma patients. (2008)
  • Author(s): Jin M, Komohara Y, Shichijo S, Nikawa J, Yamanaka R, Itoh K, Yamada A.
  • Journal Title: Cancer Scl. 99(8) Pages: 1656-1662
  • Peer Reviewed
• [Presentation] がんワクチン療法の現状と展望 (2011)
  • Author(s): 山田亮
  • Organizer: 第29回日本口腔腫瘍学会総会・学術大会
  • Place of Presentation: 崇城大学市民ホール(熊本県)(招待講演)
  • Year and Date: 2011-01-27
• [Presentation] がんワクチン療法の現状と展望 (2011)
  • Author(s): 山田亮
  • Organizer: 第29回日本言腔腫瘍学会総会・学術大会
  • Place of Presentation: 崇城大学市民ホール(熊本県)(招待講演)
  • Year and Date: 2011-01-27
• [Presentation] Development of peptide vaccine therapy for cancer (2010)
  • Author(s): 山田亮、野口正典、伊東恭悟
  • Organizer: 第69回日本癌学会学術総会
  • Place of Presentation: RIHGA Royal Hotel Osaka(大阪府)
  • Year and Date: 2010-07-22
• [Presentation] テーラーメイドペプチドワクチンの新たな展開 (2010)
  • Author(s): 山田亮、伊東恭悟
  • Organizer: 第14回日本がん免疫学会総会
  • Place of Presentation: KKRホテル熊本(熊本県)
  • Year and Date: 2010-07-22
• [Presentation] 胆道がんに対するテーラーメイドペプチドワクチン治療 (2010)
  • Author(s): 吉富宗宏、由谷茂、吉山康一、峯孝志、山田亮、小松誠和、七條茂樹、伊東恭悟、木下壽文、野口正典
  • Organizer: 第14回日本がん免疫学会総会
  • Place of Presentation: KKRホテル熊本(熊本県)
  • Year and Date: 2010-07-22
• [Presentation] 標準治療抵抗性肺がんに対するテーラーメイドペプチドワクチン療法第2相臨床試験 (2010)
  • Author(s): 吉山康一、高森信三、寺崎泰宏、山田亮、由谷茂、小松誠和、七條茂樹、伊東恭悟、野口正典、白水和雄
  • Organizer: 第14回日本がん免疫学会総会
  • Place of Presentation: KKRホテル熊本(熊本県)
  • Year and Date: 2010-07-22
• [Presentation] 婦人科癌におけるテーラーメイドがんペプチドワクチン療法の第II相臨床試験(中間報告) (2010)
  • Author(s): 河野光一郎、津田尚武、牛嶋公生、小松誠和、山田亮、伊東恭悟、嘉村敏治
  • Organizer: 第14回日本がん免疫学会総会
  • Place of Presentation: KKRホテル熊本(熊本県)
  • Year and Date: 2010-07-22
• [Presentation] ドセタキセル抵抗性再燃前立腺がんに対するテーラーメイドペプチドワクチン第II相臨床試験 (2010)
  • Author(s): 守屋普久子、末金茂高、山田亮、小松誠和、笹田哲朗、七條茂樹、伊東恭悟、野口正典
  • Organizer: 第14回日本がん免疫学会総会
  • Place of Presentation: KKRホテル熊本(熊本県)
  • Year and Date: 2010-07-22
• [Presentation] 膵臓癌におけるテーラーメイドペプチドワクチンとゲムシタビンの併用療法第II相臨床試験 (2009)
  • Author(s): 小松誠和、柳本泰明、山田亮、七條茂樹、伊東恭悟
  • Organizer: 第68回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2009-10-02
• [Presentation] ホルモン不応性再燃前立腺がんに対するテーラーメイドがんペプチドワクチン療法のランダム化比較試験 (2009)
  • Author(s): 山田亮、野口正典、小松誠和、伊東恭悟
  • Organizer: 第68回日本癌学会学術総会
  • Place of Presentation: パシフィコ横浜(神奈川県)
  • Year and Date: 2009-10-01
• [Presentation] がんワクチン開発の現状と展望 (2009)
  • Author(s): 山田亮
  • Organizer: 第16回薬と医療シンポジウム
  • Place of Presentation: 兵庫医療大学オクタホール(兵庫県)
  • Year and Date: 2009-08-29
• [Presentation] Immunological and clinical effects of personalized peptide vaccine for advanced cancer (2009)
  • Author(s): 山田亮、野口正典、藤堂省、柳本泰明、山中龍也、岡正朗、松本和将、峯孝志、松岡啓、伊東恭悟
  • Organizer: 第12回基盤的癌免疫研究会総会
  • Place of Presentation: 大宮ソニックシティ(埼玉県)
  • Year and Date: 2009-07-03
• [Presentation] 2年以上の長期テーラーメイド型ペプチドワクチン療法を行った進行再燃前立腺癌患者の免疫学的検討 (2009)
  • Author(s): 野口正典、末金茂高、守屋普久子、山田亮、伊東恭悟、松岡啓
  • Organizer: 第12回基盤的癌免疫研究会総会
  • Place of Presentation: 大宮ソニックシティ(埼玉県)
  • Year and Date: 2009-07-03
• [Presentation] テーラーメイドペプチドワクチン療法の現状と展望 (2009)
  • Author(s): 山田亮
  • Organizer: 第13回日本がん免疫学会総会
  • Place of Presentation: 北九州(福岡県)
  • Year and Date: 2009-06-24
• [Presentation] MVAC耐性進行・再発膀胱癌に対するテーラーメイド癌ペプチドワクチン療法の検討 (2009)
  • Author(s): 松本和将、佐藤威文、岩村正嗣、小松誠和、峯孝志、山田亮、伊東恭悟、馬場志郎
  • Organizer: 第13回日本がん免疫学会総会
  • Place of Presentation: 北九州(福岡県)
  • Year and Date: 2009-06-24
• [Presentation] テーラーメイドがんペプチドワクチン:実用化の展望 (2009)
  • Author(s): 山田亮、野口正典、由谷茂、伊東恭悟
  • Organizer: 第46回日本臨床分子医学会学術集会
  • Place of Presentation: 東京国際フォーラム(東京都)
  • Year and Date: 2009-04-12
• [Presentation] C型肝炎ウイルス感染者に対する治療を目的としたペプチドワクチンの臨床試験 (2008)
  • Author(s): 山田亮、由谷茂、佐田通夫、伊東恭悟
  • Organizer: 第67回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2008-10-30
• [Presentation] テーラーメイド癌ペプチドワクチン臨床試験の生存解析:475症例でのアップデート (2008)
  • Author(s): 峯孝志、野口正典、藤堂省、柳本泰明、植村天受、山中龍也、嘉村敏治、岡正朗、奥野清隆、松本和将、山田亮、伊東恭悟
  • Organizer: 第67回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2008-10-30
• [Presentation] Clinical trial of therapeutic peptide vaccine of Hepatitis C virus infection. (2008)
  • Author(s): 山田亮, 由谷茂, 佐田通夫, 伊東恭悟
  • Organizer: 第67回日本癌学会学術総会
  • Place of Presentation: 名古屋
  • Year and Date: 2008-10-30
• [Presentation] Determination of vaccine candidates for HLA-A26 positive patients with prostate cancer or HCV-related diseases. (2008)
  • Author(s): 牛亜梅, 寺崎康展, 小松誠和, 野口正典, 七條茂樹, 山田亮, 伊東恭悟
  • Organizer: 第67回日本癌学会学術総会
  • Place of Presentation: 名古屋
  • Year and Date: 2008-10-30
• [Presentation] HLA-A26前立腺癌患者およびHCV感染者に対するワクチン候補ペプチドの解析 (2008)
  • Author(s): 牛亜梅、寺崎康展、小松誠和、野口正典、七條茂樹、山田亮、伊東恭悟
  • Organizer: 第67回日本癌学会学術総会
  • Place of Presentation: 名古屋国際会議場(愛知県)
  • Year and Date: 2008-10-29
• [Remarks] ホームページ等
• [Remarks] 久留米大学先端癌治療研究センター
  • URL: http://www.med.kurume-u.ac.jp/med/sentanca/index.html
• [Remarks] 久留米大学免疫・免疫治療学講座
  • URL: http://www.med.kurume-u.ac.jp/med/immun/index.html
• [Remarks] 久留米大学先端癌治療研究センター
  • URL: http://www.med.kurume-u.ac.jp/med/sentanca/index.html
• [Remarks] 久留米大学免疫・免疫治療学講座
  • URL: http://www.med.kurume-u.ac.jp/med/immun/index.html
• [Remarks] (久留米大学先端癌治療研究センター)
  • URL: http://www.med.kurume-u.ac.jp/med/sentanca/index.html
• [Remarks] (久留米大学免疫・免疫治療学講座)
  • URL: http://www.med.kurume-u.ac.jp/med/immun/index.html
• [Patent(Industrial Property Rights)] C型肝炎ウイルスによる肝癌の発症および再発予防ワクチン (2009)
  • Inventor(s): 伊東恭悟,佐田通夫,山田亮,由谷茂
  • Industrial Property Rights Holder: 久留米大学
  • Filing Date: 2009-10-27
• [Patent(Industrial Property Rights)] C型肝炎ウイルス由来ペプチド (2009)
  • Inventor(s): 山田亮、伊東恭悟、佐田通夫、由谷茂
  • Industrial Property Rights Holder: (株)グリーンペプタイド
  • Acquisition Date: 2009-07-17
• [Patent(Industrial Property Rights)] C型肝炎ウイルス由来ペプチド (2009)
  • Inventor(s): 山田亮、伊東恭悟、佐田通夫、由谷茂
  • Industrial Property Rights Holder: (株)グリーンペプタイド
  • Acquisition Date: 2009-07-17
• [Patent(Industrial Property Rights)] C型肝炎ウイルス由来ペプチド (2008)
  • Inventor(s): 山田亮、伊東恭悟、佐田通夫、由谷茂
  • Industrial Property Rights Holder: (株)グリーンペプタイド
  • Filing Date: 2008-09-16
• [Patent(Industrial Property Rights)] C型肝炎ウイルス由来ペプチド (2008)
  • Inventor(s): 山田亮、伊東恭悟、佐田通夫、由谷茂
  • Industrial Property Rights Holder: (株)グリーンペプタイド
  • Filing Date: 2008-12-15
• [Patent(Industrial Property Rights)] C型肝炎ウイルスによる肝癌の発症および再発予防ワクチン (2008)
  • Inventor(s): 伊東恭悟,佐田通夫,山田亮,由谷茂
  • Industrial Property Rights Holder: 久留米大学
  • Industrial Property Number: 2008-276163
  • Filing Date: 2008-10-27
• [Patent(Industrial Property Rights)] C型肝炎ウイルスによる肝癌の発症および再発予防ワクチン (2008)
  • Inventor(s): 伊東恭悟, 佐田通夫, 山田亮, 由谷茂
  • Industrial Property Rights Holder: 久留米大学
  • Industrial Property Number: 2008-276163
  • Filing Date: 2008-10-27